ClinicalTrials.gg
CompletedNCT04713072Updated Feb 9, 2024

A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis

A Phase 2 interventional study of ABY-035 and Placebo in Psoriatic Arthritis, sponsored by ACELYRIN Inc.. Completed at 32 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-09.

Sponsored by ACELYRIN Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Aug 2020, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Arthritis, Psoriatic with a site in Germany — 10 open to participants now, 28 under way, 18 of them phase 3. Arthritis, Psoriatic · Germany.

Enrollment
75th of 90
129 · median 357
Started
2020
with 6 others
Phase 2
19 of 109
none open now
Registered
75th of 109
by date

Among the 109 studies in Arthritis, Psoriatic with a site in Germany, this one is the 75th largest by enrollment of the 90 interventional ones that give a count, is one of 7 that started in 2020, is one of 19 in phase 2, and was the 75th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

10 of the 109 studies in Arthritis, Psoriatic with a site in Germany are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Arthritis, Psoriatic with a site in Germany, or all of them as a file.
02

Study summary

This is a Phase II, prospective, multicenter, randomized, double-blind, placebo-controlled, dose finding trial in parallel-groups with primary endpoint at Week 16 (visit V9) to investigate the efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035 in adult patients with PsA.

Read the detailed description

The study evaluates two dose levels of ABY-035, in comparison to placebo, in subjects with psoriatic arthritis. The clinical trial duration is 72 weeks (Screening - last FU visit) comprised of up to 4 weeks of screening, 44 weeks of double-blind-treatment, and 24 weeks of follow-up.

Treatment Periods are:

  • Treatment Period I: from V1 (Week 0) to V9 (Week 16)
  • Treatment Period II: from V9 (Week 16) to V16 (Week 44: last dosing)

At visit V1 (Week 0), patients who meet the entry criteria will be randomly assigned in equal rates (1:1:1) to one of three parallel groups (A, B, C).

The treatment will be administered once every 2 weeks (Q2W).

Patients assigned to groups A and B will receive active treatment from V1 to V16 (group A = 40 mg ABY-035; group B = 80 mg ABY-035). Patients initially assigned to placebo will switch to active treatment at visit V9 in a blinded fashion (group C = Placebo from V1 to V8 and 80 mg ABY-035 from V9 to V16).

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who has given his / her signed declaration of consent and data protection declaration
  • At least 18 years and less than 75 years of age at Screening visit
  • Psoriatic arthritis with inflammatory musculoskeletal disease (joint, spine, or entheseal) with the presence of ≥3 points from the five categories of the Classification Criteria for Psoriatic Arthritis (CASPAR) at any timepoint in medical history.
  • Active psoriatic arthritis defined by:
  • ≥3 swollen joints out of 66 joints (SJC66) at Screening visit and Baseline visit
  • ≥3 tender joints out of 68 (TJC68) at Screening visit and Baseline visit
  • Precedent failure or insufficient treatment response to or or intolerability to nonsteroidal anti-inflammatory drug (NSAID), csDMARD (i.e. MTX, sulfasalazine, leflunomide, hydroxychloroquine, cyclosporine A), and/or TNFi (e.g. adalimumab, infliximab, etanercept, golimumab, certolizumab)
  • Rheumatoid factor (RF) and anti-CCP antibody negative
  • Presence or history of plaque psoriasis

Exclusion criteria

Exclusion Criteria:

  • Underlying conditions which significantly immunocompromise the patient and / or place the patient at unacceptable risk for receiving an immunomodulatory therapy
  • History of or current relevant diseases (e.g. rheumatoid arthritis, primary ankylosing spondylitis, systemic lupus erythematosus) other than psoriasis or psoriatic arthritis
  • History of or current fibromyalgia or pain syndrome
  • Uncontrolled inflammatory bowel disease
  • Presence or history of recurrent or medically important infections in the last 6 months prior to Baseline visit
  • Candida infection requiring systemic treatment within the last 6 months prior to Baseline visit
  • History or any signs of lymphoproliferative disease, or a known or a history of malignancy within the previous 5 years
  • Insufficiently controlled heart failure
  • Current uncontrolled arterial hyper- or hypotension
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    ABY-035 40 mg

    40 mg ABY-035 SC

    Biological: ABY-035

  • Experimental
    ABY-035 80 mg

    80 mg ABY-035 SC

    Biological: ABY-035

  • Placebo comparator
    Placebo

    Placebo, switching to 80 mg ABY-035 after 16 weeks

    Biological: Placebo

Interventions

  • BiologicalIzokibepStudies of IzokibepIzokibep pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ABY-035 solution for injection

  • BiologicalPlacebo

    Placebo to ABY-035 solution for injection

06

What researchers measure

Primary outcomes

  1. American College of Rheumatology 50 response rate (ACR50)

    ACR50 response rate at V9 (Week 16) for higher Dose vs. Placebo

    Time frame: 16 weeks

  2. ACR50

    ACR50 response rate at V7 (Week 12) for higher Dose vs. Placebo

    Time frame: 12 weeks

Secondary outcomes

  1. ACR20/70

    ACR20/70 response rate, percentage of patients achieving Minimal Disease Activity (MDA): at V9 (Week 16) for higher Dose vs. Placebo

    Time frame: 16 weeks

  2. ACR20/70

    ACR20/70 response rate, percentage of patients achieving MDA: at V7 (Week 12) for higher Dose vs. Placebo

    Time frame: 12 weeks

  3. ACR20/50/70

    ACR20/50/70 response rate, percentage of patients achieving MDA: at V9 (Week 16) for Lower Dose vs. Placebo

    Time frame: 16 weeks

  4. ACR20/50/70

    ACR20/50/70 response rate, percentage of patients achieving MDA: at V7 (Week 12) for Lower Dose vs. Placebo

    Time frame: 12 weeks

  5. ACR 20/50/70

    ACR 20/50/70 response rate, percentage of patients achieving MDA: at V5 (Week 8) for higher Dose vs. Placebo

    Time frame: 8 weeks

07

Study locations

32 sites
  • LKH-Univ. Klinikum Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Rheumatologie und Immunologie
    Graz, 8036, Austria
  • Medizinische Universität Innsbruck/Tirol Kliniken GmbH Universitätsklinik für Innere Medizin II
    Innsbruck, 6020, Austria
  • Vienna Medical University Department of Internal Medicine III Division of Rheumatology
    Vienna, 1090, Austria
  • Katholieke Universiteit Leuven
    Leuven, 3000, Belgium
  • VESALION s.r.o.
    Ostrava, 702 00, Czechia
  • Revmatologický ústav
    Praha, 128 00, Czechia
  • MEDICAL PLUS s.r.o.
    Uherské Hradiště, Czechia
  • PV Medical Services s.r.o.
    Zlín, 760 01, Czechia
  • Rheumatologische Schwerpunktpraxis
    Berlin, 12161, Germany
  • Schlosspark Klinik
    Berlin, 14059, Germany
  • Centrum für Innovative Diagnostik und Therapie Rheumatologie/Immunologie
    Frankfurt, 60590, Germany
  • Universitätsklinikum Freiburg
    Freiburg, 79106, Germany
  • Rheumazentrum Ruhrgebiet Herne
    Herne, 79106, Germany
  • Klinikum der Universität München Rheumatologie
    München, 80336, Germany
  • Rheumazentrum Ratingen
    Ratingen, 40878, Germany
  • Qualiclinic Kft.
    Budapest, 1036, Hungary
  • CRU Hungary Ltd
    Miskolc, 3529, Hungary
  • MÁV Kórház és Rendelőintézet, Reumtólegia
    Szolnok, 5000, Hungary
  • Vital Medical Center
    Veszprém, 8200, Hungary
  • Nasz Lekarz Ośrodek Badań Klinicznych
    Bydgoszcz, 85-065, Poland
  • PRATIA MCM Krakow
    Kraków, 30-510, Poland
  • ETYKA Ośrodek Badań Klinicznych
    Olsztyn, 10-117, Poland
  • ETG Skierniewice
    Skierniewice, 96-100, Poland
  • ETG Warszawa
    Warsaw, 02-793, Poland
  • Centrum Medyczne AMED
    Warsaw, 03-291, Poland
  • Centrum Medyczne AMED oddział w Łodzi
    Łódź, 91-363, Poland
  • Complejo Hospitalario Universitario de A Coruña
    Coruña, 15006, Spain
  • Hospital Universitario Reina Sofía 1 Planta Derecha Servicio Reumatología- IMIBIC
    Córdoba, 14004, Spain
  • Cliníca Ceta - Unidad de Ensayos Clínicos
    Madrid, 28915, Spain
  • Hospital Parc Tauli de Sabadell
    Sabadell, 8208, Spain
  • Complejo Hospitalario Universitario de Santiago de Compostela Hospital Clinico Universitario
    Santiago De Compostela, 15706, Spain
  • Hospital Quironsalud Infanta Luisa Unidad De Investigación De Reumatología
    Sevilla, 41011, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2021, 13 months.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2021
First posted
Jan 19, 2021
StartActual
Aug 4, 2020
Primary completionActual
Oct 1, 2021
CompletionActual
Jan 27, 2022
Last update
Feb 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04713072
Lead sponsor
ACELYRIN Inc.
Responsible party
Sponsor
First posted
Jan 19, 2021
Start date
Aug 4, 2020
Primary completion
Oct 1, 2021
Completion
Jan 27, 2022
Last update
Feb 9, 2024

Study contacts

Myreen Tomas, MD
study director · ACELYRIN Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izokibep

Start the discussion